A Synthetic Non-degradable Polyethylene Glycol Hydrogel Retards Adverse Post-infarct Left Ventricular Remodeling

Journal of Cardiac Failure

Volumn 15, Issue 7, 2009, Pages 629-636

  Dobner, Stephan ^a   Bezuidenhout, Deon ^a   Govender, Padmini ^a   Zilla, Peter ^a   Davies, Neil ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Myocardial infarction biomaterial

Indexed keywords

BIOMATERIAL; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; CONTROLLED STUDY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HYDROGEL; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; HYDROGELS; MALE; MYOCARDIAL INFARCTION; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 68849129381     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.03.003     Document Type: Article

References (41)

1. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. McMurray J.J., and Pfeffer M.A. Heart failure. Lancet 365 (2005) 1877-1889
3. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
4. Konstam M.A. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 96 (2005) 867-871
5. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 (2000) 569-582
6. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
7. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993) 821-828
8. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
9. Konstam M.A., Kronenberg M.W., Rousseau M.F., Udelson J.E., Melin J., Stewart D., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 88 (1993) 2277-2283
10. Greenberg B., Quinones M.A., Koilpillai C., Limacher M., Shindler D., Benedict C., et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91 (1995) 2573-2581
11. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 349 (1997) 375-380
12. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., and Eichhorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25 (1995) 1154-1161
13. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
14. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
15. Creemers E.E., Cleutjens J.P., Smits J.F., and Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 89 (2001) 201-210
16. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87 (2007) 1285-1342
17. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 108 (2003) 1395-1403
18. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
19. Konstam M.A., Udelson J.E., and Sharpe N. Prevention and reversal of left ventricular remodeling: summation. J Card Fail 8 (2002) S506-S511
20. Mann D.L., and Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111 (2005) 2837-2849
21. Opie L.H., Commerford P.J., Gersh B.J., and Pfeffer M.A. Controversies in ventricular remodelling. Lancet 367 (2006) 356-367
22. Fuchs S., Baffour R., Zhou Y.F., Shou M., Pierre A., Tio F.O., et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 37 (2001) 1726-1732
23. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9 (2003) 1195-1201
24. Grossman W., Jones D., and McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56 (1975) 56-64
25. Wall S.T., Walker J.C., Healy K.E., Ratcliffe M.B., and Guccione J.M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 114 (2006) 2627-2635
26. Kofidis T., Lebl D.R., Martinez E.C., Hoyt G., Tanaka M., and Robbins R.C. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 112 (2005) I173-I177
27. Dai W., Wold L.E., Dow J.S., and Kloner R.A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol 46 (2005) 714-719
28. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 117 (2008) 1388-1396
29. Christman K.L., Vardanian A.J., Fang Q., Sievers R.E., Fok H.H., and Lee R.J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 44 (2004) 654-660
30. Christman K.L., and Lee R.J. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 48 (2006) 907-913
31. Lutolf M.P., and Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 23 (2005) 47-55
32. Sanborn T.J., Messersmith P.B., and Barron A.E. In situ crosslinking of a biomimetic peptide-PEG hydrogel via thermally triggered activation of factor XIII. Biomaterials 23 (2002) 2703-2710
33. Lutolf M.P., Lauer-Fields J.L., Schmoekel H.G., Metters A.T., Weber F.E., Fields G.B., et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci U S A 100 (2003) 5413-5418
34. Segers V.F., Tokunou T., Higgins L.J., MacGillivray C., Gannon J., and Lee R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 116 (2007) 1683-1692
35. Takagawa J., Zhang Y., Wong M.L., Sievers R.E., Kapasi N.K., Wang Y., et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol 102 (2007) 2104-2111
36. Zisch A.H., Lutolf M.P., and Hubbell J.A. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol 12 (2003) 295-310
37. Tirelli N., Lutolf M.P., Napoli A., and Hubbell J.A. Poly(ethylene glycol) block copolymers. J Biotechnol 90 (2002) 3-15
38. Sabatine M.S., Morrow D.A., Higgins L.J., MacGillivray C., Guo W., Bode C., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
39. Christman K.L., Fok H.H., Sievers R.E., Fang Q., and Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 10 (2004) 403-409
40. Twardowski T., Fertala A., Orgel J.P., and San Antonio J.D. Type I collagen and collagen mimetics as angiogenesis promoting superpolymers. Curr Pharm Des 13 (2007) 3608-3621
41. Nicolosi G.L., Latini R., Marino P., Maggioni A.P., Barlera S., Franzosi M.G., et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 17 (1996) 1646-1656